TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03847519
Drug: ADXS-503
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
Study: NCT03847519
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a programmed death receptor-1 (PD-1)- blocking antibody.
Study: NCT00752219
Drug: ceftazidime/NXL104 + metronidazole
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV TID
Study: NCT00752219
Drug: meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV TID
Study: NCT03604744
Drug: LSD
Normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 0.1 mg per os, single dose
Study: NCT03604744
Drug: LSD
Normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 0.2 mg per os, single dose
Study: NCT03604744
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 15 mg per os, single dose
Study: NCT03604744
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 30 mg per os, single dose
Study: NCT01942369
Drug: Triptorelin Acetate 3.75mg intramuscular injection
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks.
Study: NCT00425555
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04273061
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated
Study: NCT00935883
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
Study: NCT03421353
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement.
Study: NCT03421353
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be infused over 30-60 minutes on Day 1.
Study: NCT03421353
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
Study: NCT03421353
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
Study: NCT03421353
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
Study: NCT02754297
Drug: 177Lu-Octreotate
Normalized name: 177Lu-DOTA-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles.
Study: NCT02510586
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
Study: NCT01148771
Drug: ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 gram IV bolus every 24 hours (q24h) for 3 days
Study: NCT01148771
Drug: ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 gram 30 minute infusion q24h for 3 days
Study: NCT00849992
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod 5% cream used three days a week for 4 weeks
Study: NCT01381679
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
Study: NCT00420537
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine trough levels between 100 and 150
Study: NCT00420537
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine trough levels between 40 and 90 ng/ml
Study: NCT00420537
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate with low doses
Study: NCT00420537
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01505855
Drug: 23-valent polysaccharide pneumococcal vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
Study: NCT01208766
Drug: Bortezomib, Melphalan, Prednisone (VMP)
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32~* Melphalan _ 9 mg/m² _ p.o. _ days 1-4~* Prednisone _ 60 mg/m² _ p.o. _ days 1-4
Study: NCT01208766
Drug: 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11~* Lenalidomide _ 25 mg _ p.o. _ days 1-21~* Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12
Study: NCT04318938
Drug: Brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Brigatinib
Study: NCT03090165
Drug: ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400mg PO
Study: NCT03090165
Drug: ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600mg PO
Study: NCT03090165
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg PO
Study: NCT04501120
Drug: APG-2575
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-2575 orally once daily, every 28 days as a cycle.
Study: NCT04501120
Drug: Reduced-dose HHT
Normalized name: HHT
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg IV QD on Days 1-14 (28-day cycle).
Study: NCT04501120
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
Study: NCT04501120
Drug: APG-2575
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-2575 orally once daily for 14 days, every 28 days as a cycle.
Study: NCT04391569
Drug: Ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganaxolone will be administered.
Study: NCT00738660
Drug: Telmisartan, Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
Study: NCT00829868
Drug: Zaleplon 10 mg Capsules
Normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT01446523
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup 30 ml BD for 12 weeks
Study: NCT00061711
Drug: Hormone Replacement Therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00061711
Drug: Cimicifuga racemosa (Black Cohosh)
Normalized name: Cimicifuga racemosa extract
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03198143
Drug: Ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
Study: NCT03198143
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
Study: NCT00356187
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00455702
Drug: d-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg dose d-cycloserine v placebo
Study: NCT01362790
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
Study: NCT02943473
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.
Study: NCT03256487
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine 0.3mg IV
Study: NCT03256487
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 0.1 mg/kg IV (max 8mg per dose)
Study: NCT02038647
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib tablets
Study: NCT02038647
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel intravenous injection
Study: NCT03809533
Drug: sofosbuvir/velpatasvir
Normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12-week, oral, fixed-dose
Study: NCT02284893
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT02284893
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered orally once daily
Study: NCT02284893
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administered orally once daily
Study: NCT02284893
Drug: Placebo matching with Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT02284893
Drug: Placebo matching with Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered orally once daily
Study: NCT02284893
Drug: Placebo matching with Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administered orally once daily
Study: NCT01061788
Drug: AMG 479, Everolimus, Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level
Study: NCT02412982
Drug: Enoxaparin 40 mg q12h
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
Study: NCT02412982
Drug: Enoxaparin 30 mg q8h
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive enoxaparin 30 mg every 8 hours.
Study: NCT00593619
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg in 250cc normal saline given over 2 hours
Study: NCT00593619
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg in 250cc normal saline given over 2 hours
Study: NCT00044785
Drug: triacetyluridine
Normalized name: Triacetyluridine
DrugBank: Uridine triacetate (DB09144)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00044785
Drug: camptosar
Normalized name: Camptosar
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03598348
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250mg po Qd
Study: NCT02444260
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
Study: NCT02444260
Drug: Intravenous Normal Saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline will be infused by non-blinded anaesthetist
Study: NCT02444260
Drug: Lignocaine HCl
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
Study: NCT04681170
Drug: Lomitapide
Normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg,5mg, 10mg and 20mg capsules
Study: NCT00725855
Drug: MEM 3454
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dose
Study: NCT00725855
Drug: MEM 3454
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose
Study: NCT00725855
Drug: MEM 3454
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dose
Study: NCT00725855
Drug: MEM 3454
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dose
Study: NCT00386581
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03935347
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03935347
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04233892
Drug: CBD-bFGF
Normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
Study: NCT04233892
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive regular estrogen therapy
Study: NCT01334879
Drug: ranibizumab 2.0 mg
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal ranibizumab (2.0 mg)
Study: NCT01408030
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1% solution in saline, 0.1 ml spray in each nostril bid
Study: NCT01408030
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10% solution in saline, 0.1 ml spray in each nostril bid
Study: NCT01169610
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
Study: NCT01096121
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day
Study: NCT04142554
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
Study: NCT02675413
Drug: Dimethyl Fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label
Study: NCT02048540
Drug: docetaxel oxaliplatin 5-FU CF
Normalized name: 5-FU
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
Study: NCT01682902
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
Study: NCT01682902
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
Study: NCT02382146
Drug: dexamethasone ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
Study: NCT02382146
Drug: Dexamethasone dimenhidrinate
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
Study: NCT01111552
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram oral capsules.
Study: NCT01111552
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole oral capsules.
Study: NCT01555580
Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
Study: NCT02422108
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05535569
Drug: Nivolumab, Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.